Skip to main content

Alnylam Pharmaceuticals, Inc. (ALNY) Stock

Alnylam Pharmaceuticals, Inc. Stock Details, Movements and Public Alerts

Stock Details

Alnylam Pharmaceuticals, Inc. (ALNY), a prominent company in the healthcare sector within the biotechnology industry, is based in United States and primarily trades on the NMS.Currently, the stock is trading at $204.48. Over the past 52 weeks, it has ranged between $197.81 and $495.55. This places the current price at 41.3% of its 52-week high and 3.4% above its 52-week low. Recent trading volume was recorded at 3,229,198. The 14-day Relative Strength Index (RSI) stands at 23.52, suggesting oversold conditions. The stock is currently trading below its 50-day moving average of $289.90 by 29.47%. Similarly, it is below its 200-day moving average of $350.59 by 41.68%. The MACD histogram is -4.33, indicating bearish momentum (MACD Line: -10.44, Signal Line: -6.11).

52-Week Range

$495.55 - $197.81

-58.74% from high · +3.37% from low

Avg Daily Volume

1,989,443

20-day average

100-day avg: 1,314,879

Fundamentals

Valuation Metrics

P/E Ratio (TTM)

71.85

Above market average

Forward P/E

15.63

Earnings expected to grow

PEG Ratio

0.52

Potentially undervalued

Price to Book

25.50

EV/EBITDA

47.37

EPS (TTM)

$2.86

Price to Sales

6.40

Beta

0.27

Less volatile than market

Q:How is ALNY valued relative to its earnings and growth?
Alnylam Pharmaceuticals, Inc. trades at a P/E ratio of 71.85, which is above the market average of approximately 20. This premium valuation suggests investors expect above-average growth or the company has competitive advantages justifying the higher multiple. Looking ahead, the forward P/E of 15.63 is lower than the current P/E, indicating analysts expect earnings to grow over the next year. The PEG ratio of 0.52 suggests the stock may be undervalued relative to its growth rate.
Q:What is ALNY's risk profile compared to the market?
With a beta of 0.27, Alnylam Pharmaceuticals, Inc. is less volatile than the overall market. This means when the market moves up or down by 10%, this stock typically moves less than 10% in the same direction. Lower beta stocks are often preferred by conservative investors seeking stability. The price-to-book ratio of 25.50 shows investors value the company above its book value, which often reflects intangible assets or growth prospects.

Performance & Growth

Profit Margin

12.55%

Operating Margin

23.02%

EBITDA

$806.94M

Return on Equity

90.36%

Return on Assets

10.06%

Revenue Growth (YoY)

96.40%

Q:How profitable and efficient is ALNY's business model?
Alnylam Pharmaceuticals, Inc. achieves a profit margin of 12.55%, meaning it retains $12.55 from every $100 in revenue after all expenses. This represents a solid margin typical of well-run businesses, showing the company can effectively balance revenue generation with cost control. The operating margin of 23.02% reveals how efficiently the company runs its core business operations before interest and taxes. With ROE at 90.36% and ROA at 10.06%, the company generates strong returns on invested capital.
Q:What are ALNY's recent growth trends?
Alnylam Pharmaceuticals, Inc.'s revenue grew by 96.40% year-over-year, representing robust expansion that significantly outpaces typical market growth rates. This strong top-line performance suggests the company is successfully capturing market share or benefiting from favorable industry trends. These growth metrics should be evaluated against Biotechnology industry averages for proper context.

Company Size & Market

Market Cap

$27.4B

Revenue (TTM)

$4.29B

Revenue/Share (TTM)

$32.52

Shares Outstanding

133.51M

Book Value/Share

$8.06

Asset Type

EQUITY

Q:What is ALNY's market capitalization and position?
Alnylam Pharmaceuticals, Inc. has a market capitalization of $27.4B, classifying it as a large-cap stock ($10B-$200B). Large-caps are typically industry leaders with established business models, offering a balance of stability and growth potential. They often provide dividend income and are core holdings in institutional portfolios. With 133.51M shares outstanding, the company's ownership is relatively concentrated. As a participant in the Biotechnology industry, it competes with other firms in this sector.
Q:How does ALNY's price compare to its book value?
Alnylam Pharmaceuticals, Inc.'s book value per share is $8.06, while the current stock price is $204.48, resulting in a price-to-book (P/B) ratio of 25.37. This high P/B ratio indicates significant intangible assets, strong brand value, or high growth expectations. Technology and consumer brand companies often trade at elevated P/B ratios due to intellectual property and competitive advantages not reflected on the balance sheet. As EQUITY, this represents a specific type of security.

Analyst Ratings

Analyst Target Price

$427.61

109.12% upside potential

Analyst Recommendations

Strong Buy

6

Buy

14

Hold

8

Sell

0

Strong Sell

0

Q:How reliable are analyst predictions for ALNY?
28 analysts cover ALNY with 71% recommending buy/strong buy ratings. Analyst predictions have mixed reliability - studies show consensus rarely beats market returns consistently. The strong bullish consensus may already be priced in. The consensus target of $427.61 implies 109.1% upside, but targets are often adjusted to follow price moves rather than predict them.
Q:What is the Wall Street consensus on ALNY?
Current analyst recommendations:6 Strong Buy, 14 Buy, 8 Hold, 00The bullish tilt suggests optimism about future prospects, though investors should conduct independent research.Remember that analyst opinions often lag price movements and can be influenced by investment banking relationships.

Fundamentals last updated: Jul 31, 2026, 02:12 AM

Technical Indicators

RSI (14-day)

23.52

Oversold

50-Day Moving Average

$289.90

-29.47% below MA-50

200-Day Moving Average

$350.59

-41.68% below MA-200

MACD Line

-10.44

MACD Signal

-6.11

MACD Histogram

-4.33

Bearish

Q:What does ALNY's RSI value tell investors?
The RSI (Relative Strength Index) for ALNY is currently 23.52, indicating the stock is in oversold territory (below 30). This indicates heavy selling pressure that may have pushed the price too low too fast. Oversold readings can present buying opportunities, but stocks can remain oversold in strong downtrends. Look for RSI to rise above 30 as a potential recovery signal. Combined with the price being below the 50-day moving average, this confirms bearish conditions.
Q:How should traders interpret ALNY's MACD and moving average crossovers?
MACD analysis shows the MACD line at -10.44 below the signal line at -6.11, with histogram at -4.33. This bearish crossover indicates downward pressure. The wide histogram confirms strong momentum. The 50-day MA ($289.90) is below the 200-day MA ($350.59), forming a death cross pattern that often warns of extended weakness. Price is currently below both MAs, confirming weakness.

Indicators last updated: Jul 31, 2026, 01:14 AM

Active Alerts

No active alerts for this stock.

Be the first to set up an alert for ALNY and get notified when the price changes.

Stay Ahead of the Market with Alnylam Pharmaceuticals, Inc. Alerts

Set up price alerts for Alnylam Pharmaceuticals, Inc. and get notified instantly when the price hits your target. Never miss an important price movement again.